Literature for ONX 0914 (T01.010, T01.011, T01.012 inhibitor)

Summary Structure Literature

(Topics flags: S Structure, K Knockout, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019

Zerfas,B.L. and Trader,D.J.
Synthesis and application of an activity-based peptide-peptoid hybrid probe for the immunoproteasome
Curr Protoc Chem Biol11, e76-e76. PubMed Europe PubMed DOI I

2018

Bakas,N.A., Schultz,C.R., Yco,L.P., Roberts,C.C., Chang,C.A., Bachmann,A.S. and Pirrung,M.C.
Immunoproteasome inhibition and bioactivity of thiasyrbactins
Bioorg Med Chem26, 401-412. PubMed Europe PubMed DOI I
Ogorevc,E., Schiffrer,E.S., Sosic,I. and Gobec,S.
A patent review of immunoproteasome inhibitors
Expert Opin Ther Pat28, 517-540. PubMed Europe PubMed DOI I

2017

Koerner,J., Brunner,T. and Groettrup,M.
Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice
Oncotarget8, 50873-50888. PubMed Europe PubMed DOI I
Liu,H., Wan,C., Ding,Y., Han,R., He,Y., Xiao,J. and Hao,J.
PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production
FASEB J31, 1756-1766. PubMed Europe PubMed DOI I
Vachharajani,N., Joeris,T., Luu,M., Hartmann,S., Pautz,S., Jenike,E., Pantazis,G., Prinz,I., Hofer,M.J., Steinhoff,U. and Visekruna,A.
Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7
Oncotarget8, 50447-50459. PubMed Europe PubMed DOI K I
von Brzezinski,L., Saring,P., Landgraf,P., Cammann,C., Seifert,U. and Dieterich,D.C.
Low neurotoxicity of ONX-0914 supports the idea of specific immunoproteasome inhibition as a side-effect-limiting, therapeutic strategy
Eur J Microbiol Immunol (Bp)7, 234-245. PubMed Europe PubMed DOI I

2015

Harshbarger,W., Miller,C., Diedrich,C. and Sacchettini,J.
Crystal structure of the human 20S proteasome in complex with carfilzomib
Structure23, 418-424. PubMed Europe PubMed DOI S I
Huber,E.M., Heinemeyer,W. and Groll,M.
Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914
Structure23, 407-417. PubMed Europe PubMed DOI S I
Zilberberg,J., Matos,J., Dziopa,E., Dziopa,L., Yang,Z., Kirk,C.J., Assefnia,S. and Korngold,R.
Inhibition of the immunoproteasome subunit LMP7 with ONX 0914 ameliorates graft-versus-host disease in an MHC-matched minor histocompatibility antigen-disparate murine model
Biol Blood Marrow Transplant21, 1555-1564. PubMed Europe PubMed DOI I

2014

Basler,M., Mundt,S., Muchamuel,T., Moll,C., Jiang,J., Groettrup,M. and Kirk,C.J.
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis
EMBO Mol Med6, 226-238. PubMed Europe PubMed DOI I
Kisselev,A.F. and Groettrup,M.
Subunit specific inhibitors of proteasomes and their potential for immunomodulation
Curr Opin Chem Biol23, 16-22. PubMed Europe PubMed DOI I
Niewerth,D., Kaspers,G.J., Assaraf,Y.G., van Meerloo,J., Kirk,C.J., Anderl,J., Blank,J.L., van de Ven,P.M., Zweegman,S., Jansen,G. and Cloos,J.
Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
J Hematol Oncol7, 7-7. PubMed Europe PubMed DOI I
Stein,M.L. and Groll,M.
Applied techniques for mining natural proteasome inhibitors
Biochim Biophys Acta1843, 26-38. PubMed Europe PubMed DOI I

2012

Huber,E.M., Basler,M., Schwab,R., Heinemeyer,W., Kirk,C.J., Groettrup,M. and Groll,M.
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity
Cell148, 727-738. PubMed Europe PubMed DOI S I
Ichikawa,H.T., Conley,T., Muchamuel,T., Jiang,J., Lee,S., Owen,T., Barnard,J., Nevarez,S., Goldman,B.I., Kirk,C.J., Looney,R.J. and Anolik,J.H.
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
Arthritis Rheum64, 493-503. PubMed Europe PubMed DOI I
Nagayama,Y., Nakahara,M., Shimamura,M., Horie,I., Arima,K. and Abiru,N.
Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice
Clin Exp Immunol168, 268-273. PubMed Europe PubMed DOI I
Verbrugge,S.E., Assaraf,Y.G., Dijkmans,B.A., Scheffer,G.L., Al,M., den Uyl,D., Oerlemans,R., Chan,E.T., Kirk,C.J., Peters,G.J., van der Heijden,J.W., de Gruijl,T.D., Scheper,R.J. and Jansen,G.
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis
J Pharmacol Exp Ther341, 174-182. PubMed Europe PubMed DOI I

2010

Basler,M., Dajee,M., Moll,C., Groettrup,M. and Kirk,C.J.
Prevention of experimental colitis by a selective inhibitor of the immunoproteasome
J Immunol185, 634-641. PubMed Europe PubMed DOI I

2009

Muchamuel,T., Basler,M., Aujay,M.A., Suzuki,E., Kalim,K.W., Lauer,C., Sylvain,C., Ring,E.R., Shields,J., Jiang,J., Shwonek,P., Parlati,F., Demo,S.D., Bennett,M.K., Kirk,C.J. and Groettrup,M.
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Nat Med15, 781-787. PubMed Europe PubMed DOI I
Zhou,H.J., Aujay,M.A., Bennett,M.K., Dajee,M., Demo,S.D., Fang,Y., Ho,M.N., Jiang,J., Kirk,C.J., Laidig,G.J., Lewis,E.R., Lu,Y., Muchamuel,T., Parlati,F., Ring,E., Shenk,K.D., Shields,J., Shwonek,P.J., Stanton,T., Sun,C.M., Sylvain,C., Woo,T.M. and Yang,J.
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)
J Med Chem52, 3028-3038. PubMed Europe PubMed DOI I